22. Immune responses to malignancies
- PMID: 12592313
- DOI: 10.1067/mai.2003.90
22. Immune responses to malignancies
Abstract
Immune responses to tumor-associated antigens exist in tumor-bearing hosts but are usually not successful in eliminating malignant cells or preventing the development of metastases. Patients with cancer generate robust immune responses to infectious agents (bacteria and viruses) perceived as a "danger signal" but only ineffective, weak responses to tumor-associated antigens, which are considered as "self." This fundamental difference in responses to self versus non-self is further magnified by the ability of tumors to subvert the host immune system. Tumors induce dysfunction, as well as apoptosis in CD8(+) antitumor effector cells. The escape of tumors from immune cells is mediated by several distinct molecular mechanisms. Insights into these mechanisms and more effective control of tumor-orchestrated immune dysfunction are needed. Novel strategies for immunotherapy of cancer must address protection and survival of antitumor effector cells in the tumor microenvironment.
Similar articles
-
Immune responses to malignancies.J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S272-83. doi: 10.1016/j.jaci.2009.09.045. Epub 2010 Jan 12. J Allergy Clin Immunol. 2010. PMID: 20061007 Free PMC article. Review.
-
Immunological responses can have both pro- and antitumour effects: implications for immunotherapy.Expert Rev Mol Med. 2007 Feb 7;9(4):1-20. doi: 10.1017/S1462399407000233. Expert Rev Mol Med. 2007. PMID: 17284328 Review.
-
Tumor-host immune interactions and dendritic cell dysfunction.Adv Cancer Res. 2004;92:13-27. doi: 10.1016/S0065-230X(04)92002-7. Adv Cancer Res. 2004. PMID: 15530555 Review.
-
Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.Semin Cancer Biol. 2006 Feb;16(1):3-15. doi: 10.1016/j.semcancer.2005.07.008. Epub 2005 Sep 8. Semin Cancer Biol. 2006. PMID: 16153857 Review.
-
Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance.J Clin Oncol. 2004 Mar 15;22(6):1136-51. doi: 10.1200/JCO.2004.10.041. J Clin Oncol. 2004. PMID: 15020616 Review.
Cited by
-
Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients.Gastric Cancer. 2013 Oct;16(4):473-9. doi: 10.1007/s10120-012-0210-1. Epub 2012 Nov 22. Gastric Cancer. 2013. PMID: 23179366
-
Aberrant methylation of FAT4 and SOX11 in peripheral blood leukocytes and their association with gastric cancer risk.J Cancer. 2018 Jun 5;9(13):2275-2283. doi: 10.7150/jca.24797. eCollection 2018. J Cancer. 2018. PMID: 30026822 Free PMC article.
-
CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients.Cancer Immunol Immunother. 2008 Mar;57(3):399-409. doi: 10.1007/s00262-007-0382-4. Epub 2007 Aug 24. Cancer Immunol Immunother. 2008. PMID: 17717663 Free PMC article.
-
Stimulated monocyte IL-6 secretion predicts survival of patients with head and neck squamous cell carcinoma.BMC Cancer. 2008 Jan 30;8:34. doi: 10.1186/1471-2407-8-34. BMC Cancer. 2008. PMID: 18234094 Free PMC article.
-
Immune response, depression and fatigue in relation to support intervention in mammary cancer patients.Support Care Cancer. 2008 Jan;16(1):57-65. doi: 10.1007/s00520-007-0275-2. Epub 2007 Jun 12. Support Care Cancer. 2008. PMID: 17562086 Clinical Trial.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials